Limitations of the laboratory monitoring of heparin therapy

Thrombosis and Haemostasis

Volumn 87, Issue 1, 2002, Pages 163-164

  Greaves, Mike ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTHROMBIN A; TISSUE FACTOR PATHWAY INHIBITOR;

ACCURACY; ANTICOAGULATION; ASSAY; BLEEDING; BLOOD SAMPLING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DISEASE COURSE; DOSE RESPONSE; DRUG CONTROL; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; DRUG USE; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; MOLECULAR WEIGHT; PLASMA; PREDICTION; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; RECURRENT DISEASE; REVIEW; STANDARD; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

EID: 0036145979     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612960     Document Type: Review

References (23)

1. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin
2. Establishing a therapeutic range for heparin
3. Effect of clot-detection methods and reagents on APTT-implications in heparin monitoring by APTT
4. Heparin inactivation during blood storage: Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture
5. An artefact related to the sample volume to the blood collection vial size which affects the APTTs of specimens taken to monitor heparin therapy
6. Monitoring heparin therapy by the APTT - The effect of pre-analytical conditions
7. Treatment of deep venous thrombosis with low-molecular-weight heparin
8. The activity of heparin in the presence and absence of calcium ions; why the anti-Xa activity of LMW heparins is about two times overestimated
9. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma - The need for using absolute anti-factor Xa and antithrombin activities
10. A comparative study of three low-molecular weight heparins and unfractionated heparin in healthy volunteers
11. Low-molecular-weight heparins: Pharmcologic profile and product differentiation
12. A computer assisted method to obtain prothrombin activation velocity in whole plasma independent of thrombin decay process
13. The mode of action of heparin in plasma
14. The action of a synthetic pentasaccharide on thrombin generation in whole plasma
15. The mode of action of low molecular weight heparin preparation (PK1069) and two its major component on thrombin generation in plasma
16. The mode of action of CY216 and CY222 in plasma
17. Mode of action of enoxaparin in plasma
18. Anti-Xa monitoring during treatment of LMWH or danaparoid: Inter-assay variability
19. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight or heparin
20. Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage
21. Adjusted versus fixed doses of low molecular weight heparin Fragmin in the treatment of depp venous thrombosis
22. Indentification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
23. The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability